INS and type 1 diabetes mellitus: Larger prospective, randomized, placebo-controlled clinical trials are warranted in order to assess the efficacy of adding GABA, a DPP-4i and a PPI to insulin therapy as adjunct treatment for improved glycemic control, together with reduction of insulin requirements in patients with recent onset T1D.